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Objectives: To evaluate the association between improvements in clinical 
and patient-reported outcomes (PROs) and improvements in workplace and 
household productivity in axial spondyloarthritis (axSpA) patients treated with 
certolizumab pegol (CZP), including ankylosing spondylitis (AS) and non-radio-
graphic axSpA (nr-axSpA). MethOds: Analyses used Week (Wk) 24 data from 
the double-blind, placebo-controlled period of RAPID-axSpA (NCT01087762), for 
patients originally randomized to CZP. Responders and non-responders for clini-
cal outcomes and PROs were compared in terms of change from baseline (CFB) 
in workplace and household productivity, assessed with the arthritis-specific 
Work Productivity Survey (WPS). Groups were compared using a non-parametric 
bootstrap-t method. LOCF was used for ASDAS and WPS outcomes; NRI for ASAS40 
and PRO MCIDs. Results: 218 CZP patients entering RAPID-axSpA were ana-
lyzed at Wk24 (121 AS; 97 nr-axSpA). Patients employed at Wk24: 73.9% axSpA; 
73.6% AS; 74.2% nr-axSpA. Greater improvements in workplace productivity were 
reported by CZP-treated axSpA patients who achieved a clinical response (pres-
enteeism CFB [responders/non-responders]: -3.9/-1.0 for ASAS40; -4.3/-0.7 for 
ASDAS-MI) and reported improved physical function and less back pain (pres-
enteeism CFB [responders/non-responders]: -3.9/0.7 for BASFI MCID; -3.5/1.3 for 
total back pain MCID). Clinical responses and symptom relief were also associated 
with improved household productivity (CFB in days with productivity reduced 
by ≥ 50% [responders/non-responders]: -4.8/-3.6 for ASAS40; -5.1/-2.2 for BASFI 
MCID; -5.6/-0.6 for ASQoL MCID) and greater social participation (CFB in family/
social/leisure days missed [responders/non-responders]: -3.3/-1.8 for ASDAS-MI; 
-2.9/-0.8 for total back pain MCID). Nr-axSpA responders reported numerically 
greater improvements in productivity than AS responders (presenteeism CFB for 
ASDAS-MI [responders/non-responders]: -5.5/-0.5 in nr-axSpA; -3.4/-0.9 in AS). 
Results should be interpreted with caution, given differences in patient number 
between groups, and because analyses were unadjusted for baseline productiv-
ity differences. cOnclusiOns: Achievement of clinical responses and symptom 
relief were associated with increased workplace and household productivity in 
CZP-treated axSpA patients, including AS and nr-axSpA.
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Objectives: Elderly patients are at higher risk for osteoporotic (OP) fractures com-
pared with the general population[1], with low-trauma fractures in elderly patients 
associated with increased mortality risk.[2] In a high proportion of patients with 
an OP fracture, OP is previously undiagnosed and no OP-medication initiated[3]. 
This market-research aimed to assess the OP-risk in geriatric patients without 
OP-diagnosis. [1] Cooper C et al. (1992): Hip fractures in the elderly: a world-wide pro-
jection. Osteoporosis international; 2(6):285-289. [2] Bliuc et al.: Mortality risk associ-
ated with low-trauma osteoporotic fracture and subsequent fracture in men and 
women. JAMA 2009 Feb 4; 301(5):513-21. [3] Klein S et al.: Osteoporose in Deutschland 
– Epidemiologie und Versorgung, 56. GMDS Jahrestagung (2011) MethOds: New 
patients to a German geriatric-practice without OP-diagnosis, completing a ques-
tionnaire (QU) with their physician evaluating OP-risk factors determined by the 
German-S3-OP-guideline[1], e.g. age, gender, BMI, were eligible. A total of 29 ques-
tions were assigned 1 or 2 points depending on OP-risk impact (total points: 0 - 31). 
A score ≥ 3 identified “OP-suspects” who were to be referred to an orthopedist. 
In orthopedic-confirmed OP-cases, OP-medication was initiated. We present 
interim data (patients completing the QU from 10/14 to 3/15). [1] http://www.dv-
osteologie.org/uploads/Leitlinie%202014/DVO-Leitlinie%20Osteoporose%202014%20
Kurzfassung%20und%20Langfassung%2018.%2009.%202014.pdf Results: Among 
53 patients included in the interim analysis, mean age was 78 years and 40 (76%) 
were post-menopausal women; 23 (43%) had co-existing diabetes and 15 (28%) 
chronic-renal-insufficiency. One-third (17 [32%]) had experienced ≥ 1 fracture after 
the age of 50. All 53 patients were identified as “OP-suspects” (mean QU-score, 
6.6 points); 29 (55%) scored ≥ 7 points indicating very high OP-risk. To date, 26 
patients had returned to the geriatric practice, with 12 (46%) having an orthopedics-
confirmed OP-diagnosis. cOnclusiOns: Our data suggest proactive evaluation 
and identification of OP is needed in the elderly population, to improve disease 
management including initiation of therapy as appropriate.
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Objectives: Osteoporosis is a chronic progressive disease characterized by low bone 
mass and deterioration of bone structure, leading to an increate risk of fractures.The 
aim of this study was to investigate the determinants of non-persistence and impact 
of persistence on the risk of fractures. MethOds: The data used for this study were 
(DLQI), and Work Productivity and Activity Impairment Index (WPAI). Patients were 
classified as achieving: full, partial, or no benefit from treatment. Full benefit was no 
PsA flare, psoriasis body surface area (BSA) = 0; a “mild” rating of physician/patient 
global perception of PsA and all skin and joint symptoms. No benefit was a PsA flare 
or physician/patient global perception of PsA that remained “moderate/severe” or 
worsened since initiation of current therapy. Everyone else achieved partial benefit. 
HRQoL was described for those with partial benefit. Residual disease was defined 
as BSA > 0%, ≥ 1 tender or swollen joint, or ≥ 1 skin or joint symptom rated as 
“moderate/severe”. Adjusted associations were estimated between residual disease, 
HRQoL, productivity and switching. Results: The sample included 398 patients; 
19.6% achieved full, 49.0% partial, and 31.4% no benefit. Of those achieving partial 
benefit, 43.1% were female, mean (SD) age 50.1 (11.8), PsA duration in months 97.9 
(91.0), BSA 8.0% (10.2%). Mean (SD) HRQoL scores for partial benefit patients were: 
0.81 (0.20) EQ-5D; 27.01, (27.10) overall work impairment; 5.17 (5.16) DLQI; 11.03 
(12.33) PROMIS HAQ; 0.35 (0.41) HAQ-DI. Residual disease was not associated with 
switching. Residual skin disease was not associated with lower EQ5D or higher 
WPAI scores. cOnclusiOns: A substantial proportion of patients yield partial or 
full benefit from biologics. In this sample, residual skin disease did not impact 
HRQoL or work productivity.
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Objectives: To estimate the willingness-to-pay (WTP) for symptom relief of tennis 
elbow and examine whether WTP is related to injury characteristics, clinical out-
comes, or other socio-demographic factors. MethOds: This cross-sectional WTP, 
contingent valuation study was performed alongside a randomised controlled trial 
comparing the addition of physiotherapy to corticosteroid injection in 165 par-
ticipants with tennis elbow. The contingent value scenario constructed required 
participants to decide the monetary value (AUD) they would pay for a quick and 
non-invasive new treatment for relief of their elbow condition. Participants were 
told to consider that their symptoms would persist for the next 12 months if left 
untreated. The efficacy of this new treatment was defined as complete recovery in 
50% of people treated. Two WTP approaches (bidding game and binary response) 
were administrated in blocks of 15 consecutive participants. For both methods, 
participants were randomly allocated a starting bid from values of $50, $650, $1250 
or $1850. Results: The bidding game approach was performed in 73 participants. 
WTP values ranged from $50 – 10000 [median WTP (IQR): $695 ($390, $940)]. WTP was 
significantly associated with an individual’s gross income, greater pain and disabil-
ity and a worsening condition. The binary response approach was performed in 87 
participants. All participants accepted a $50 bid, while more than half accepted $650 
and $1250 bids. Using this approach, participants were more likely to accept higher 
values if they had experienced greater pain and disability, a worsening condition and 
reduced pain-free grip of their affected arm. cOnclusiOns: This study examined 
the economic value that participants with tennis elbow ascribe to relief of their 
condition. The relationship between this monetary value and an individual’s injury 
characteristics and income was also demonstrated. In future work, we propose 
to compare these WTP estimates with indicators of health-related quality-of-life, 
which were also collected during this study.
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Objectives: To evaluate the association between improvements in clinical and 
patient-reported outcomes (PROs) and improvements in workplace and household 
productivity in psoriatic arthritis (PsA) patients treated with certolizumab pegol 
(CZP). MethOds: Analyses used Week (Wk) 24 data from the double-blind, placebo-
controlled period of RAPID-PsA (NCT01087788), for patients originally randomized to 
CZP. Responders and non-responders for clinical outcomes and PROs were compared 
in terms of change from baseline (CFB) in workplace and household productivity, 
assessed with the arthritis-specific Work Productivity Survey (WPS). Groups were 
compared using a non-parametric bootstrap-t method. LOCF was used for WPS out-
comes; NRI for clinical outcomes and PRO MCIDs. Results: 273 CZP patients entering 
RAPID-PsA were analyzed at Wk24. 61.9% of patients were employed at Wk24. Greater 
improvements in workplace productivity were reported by CZP-treated patients who 
achieved improved joint and skin outcomes, as well as disease remission (absentee-
ism CFB [responders/non-responders]: -1.4/-0.5 for ACR20; -1.9/-0.4 for PASI75; -1.5/-
0.6 for DAS28 remission). Clinically meaningful reductions in disability, pain and 
fatigue were also associated with increased workplace productivity (presenteeism 
CFB [responders/non-responders]: -5.4/-0.9 for HAQ-DI MCID; -3.4/-2.6 for pain MCID; 
-4.4/-0.9 for fatigue MCID). Clinical responses and symptom relief were also associ-
ated with improved household productivity (CFB in days with productivity reduced 
by ≥ 50% [responders/non-responders]: -5.8/-1.0 for ACR20; -5.5/-0.9 for PASI75; -5.1/-
3.0 for DAS28 remission; -6.0/-1.9 for HAQ-DI MCID; -5.1/-1.3 for pain MCID; -5.1/-1.7 
for fatigue MCID) and greater social participation (CFB in family/social/leisure days 
missed [responders/non-responders]: -3.0/-1.5 for PsARC; -2.9/-2.3 for fatigue MCID). 
Results should be interpreted with caution, given differences in patient number 
between groups, and because analyses were unadjusted for baseline productivity 
differences. cOnclusiOns: Achievement of disease remission, clinically meaningful 
improvements in joint and skin outcomes and symptom relief were associated with 
increased workplace and household productivity in PsA patients treated with CZP.
